Bart Filius Buys 150,000 Shares of ProQR Therapeutics (NASDAQ:PRQR) Stock

ProQR Therapeutics N.V. (NASDAQ:PRQR) Director Bart Filius bought 150,000 shares of the company’s stock in a transaction on Friday, June 26th. The stock was bought at an average cost of $1.54 per share, with a total value of $231,000.00. Following the completion of the purchase, the director owned 150,000 shares of the company’s stock, valued at approximately $231,000. The trade was a ∞ increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

ProQR Therapeutics Trading Down 5.9%

Shares of PRQR stock opened at $1.75 on Thursday. ProQR Therapeutics N.V. has a 1 year low of $1.33 and a 1 year high of $3.10. The firm’s 50 day moving average is $1.60 and its 200-day moving average is $1.70. The firm has a market capitalization of $184.38 million, a price-to-earnings ratio of -3.50 and a beta of 0.03.

ProQR Therapeutics (NASDAQ:PRQR) last issued its quarterly earnings results on Tuesday, May 12th. The biopharmaceutical company reported ($0.15) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.15). ProQR Therapeutics had a negative net margin of 331.33% and a negative return on equity of 84.87%. The business had revenue of $2.35 million during the quarter, compared to analyst estimates of $5.19 million. On average, equities research analysts forecast that ProQR Therapeutics N.V. will post -0.52 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on PRQR shares. Oppenheimer began coverage on ProQR Therapeutics in a research report on Thursday, March 12th. They set an “outperform” rating and a $9.00 target price for the company. JonesTrading lowered their price objective on ProQR Therapeutics from $11.00 to $10.00 and set a “buy” rating for the company in a research report on Friday, June 26th. Chardan Capital dropped their price objective on ProQR Therapeutics from $4.00 to $3.00 and set a “buy” rating for the company in a report on Friday, June 26th. Wall Street Zen lowered shares of ProQR Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Saturday, May 16th. Finally, Weiss Ratings cut shares of ProQR Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, June 23rd. Five equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $7.33.

Institutional Investors Weigh In On ProQR Therapeutics

A number of institutional investors have recently made changes to their positions in PRQR. Osaic Holdings Inc. increased its holdings in ProQR Therapeutics by 59.6% in the second quarter. Osaic Holdings Inc. now owns 12,050 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 4,500 shares during the last quarter. Persistent Asset Partners Ltd boosted its holdings in ProQR Therapeutics by 24.5% during the fourth quarter. Persistent Asset Partners Ltd now owns 45,154 shares of the biopharmaceutical company’s stock worth $91,000 after buying an additional 8,874 shares during the last quarter. Diadema Partners LP grew its position in shares of ProQR Therapeutics by 6.2% during the 4th quarter. Diadema Partners LP now owns 167,532 shares of the biopharmaceutical company’s stock worth $338,000 after buying an additional 9,838 shares during the period. Bank of America Corp DE grew its position in shares of ProQR Therapeutics by 6.4% during the 1st quarter. Bank of America Corp DE now owns 185,110 shares of the biopharmaceutical company’s stock worth $300,000 after buying an additional 11,186 shares during the period. Finally, Raymond James Financial Inc. increased its stake in shares of ProQR Therapeutics by 15.2% in the 3rd quarter. Raymond James Financial Inc. now owns 110,270 shares of the biopharmaceutical company’s stock valued at $235,000 after acquiring an additional 14,549 shares during the last quarter. 32.65% of the stock is owned by institutional investors and hedge funds.

ProQR Therapeutics Company Profile

ProQR Therapeutics N.V. is a clinical-stage biotechnology company dedicated to developing RNA-based therapies for severe genetic diseases. Utilizing its proprietary Axiomer® RNA editing platform, ProQR aims to correct disease-causing mutations directly at the messenger RNA level. The company’s pipeline features several investigational candidates, including sepofarsen (formerly QR-110) for Leber congenital amaurosis type 10, QR-421a targeting Usher syndrome and certain forms of retinitis pigmentosa, and QR-313 for dystrophic epidermolysis bullosa.

Founded in 2012 and headquartered in Leiden, the Netherlands, ProQR maintains a significant presence in Cambridge, Massachusetts, to support its clinical research and regulatory initiatives.